http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101816119-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2561-113 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
| filingDate | 2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101816119-B1 |
| titleOfInvention | miR-30a as a marker for diagnosing of anti-cancer drug resistance and composition for overcoming anti-cancer drug resistance comprising it's inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for inhibiting resistance to an anticancer agent comprising, as an active ingredient, an inhibitor of miR-30a and miR-30a as an anti-cancer drug resistance diagnostic marker. Specifically, the expression of miR-30a is increased in cancer- 30a by inhibiting the expression of miR-30a or inhibiting the binding of miR-307 to miR-217 by using a method of providing information necessary for diagnosing cancer resistance of cancer patients and containing an inhibitor of miR-30a as an active ingredient And to a pharmaceutical composition exhibiting an effect of suppressing tolerance to the disease. According to the present invention, the method for measuring the expression level of miR-30a can effectively provide information on the resistance of a cancer patient to an anticancer agent, and can provide a pharmaceutical composition according to the present invention containing an inhibitor of miR-30a When used, the resistance to such anticancer agents can be effectively inhibited. In addition, an anticancer drug resistance inhibitor can be effectively screened by screening for a substance capable of inhibiting the expression of miR-30a. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019245135-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11639531-B2 |
| priorityDate | 2016-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.